Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity

Journal of Immunology

Volumn 162, Issue 1, 1999, Pages 144-151

  De Veerman, Marijke ^a   Heirman, Carlo ^a   Van Meirvenne, Sonja ^a   Devos, Sophie ^a   Corthals, Jurgen ^a   Moser, Muriel ^b   Thielemans, Kris ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARY DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; GENE TARGETING; GENETIC TRANSDUCTION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN PRESENTATION; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CELLS, CULTURED; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLONEY MURINE LEUKEMIA VIRUS; OVALBUMIN; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032953409     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
2. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.
3. Bohlen, H., K. Thielemans, H. Tesch, A. Engert, H. Wolf, B. Van Camp, J. Urbain, and V. Diehl. 1996. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype X anti-class II antibodies can protect against tumor growth. Cytokines Mol. Ther. 2:231.
4. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. Falo. 1996. Peptide-pulsed dendritic cells induce antigen-specific. CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
5. Flamand, V., T. Sornasse, K. Thielemans, C. Demanet, M. Bakkus, H. Bazin, F. Tielemans, O. Leo, J. Urbain, and M. Moser. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24:605.
6. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleoet, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
7. Mayordomo, J. I., D. J. Loftus, H. Sakamoto, C. M. De Cesare, P. M. Appasamy, M. T. Lotze, W. J. Storkus, E. Appella, and A. B. DeLeo. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357.
8. Nair, S. K., D. Boczkowski, D. Snyder, and E. Gilboa. 1997. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur. J. Immunol. 27:589.
9. Paglia, P., C. Chiodoni, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.
10. Porgador, A., D. Snyder, and E. Gilboa. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918.
11. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:98.
12. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen pulsed dendritic cells. Nat. Med. 2:52.
13. Boon, T., J. C. Cerottinni, P. Van Der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337.
14. + T cell help. J. Exp. Med. 186:65.
15. Grueder, S., and P. Matzinger. 1992. A fail-safe mechanism for maintaining self-tolerance. J. Exp. Med. 176:553.
16. Keene, J.-A., and J. Forman. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp. Med. 155:768.
17. Kern, D. E., J. P. Klarnet, M. C. V. Jensen, and P. D. Greenberg. 1986. Requirement for recognition of class II molecules and processed tumor-antigen for optimal generation of syngeneic tumor-specific class I restricted CTL. J. Immunol. 136:4303.
18. Ossendorp, F., D. Mengedé, M. Camps, R. Filius, and C. J. M. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693.
19. Nair, S., J. S. Babu, R. G. Dunham, P. Kanda, R. L. Burke, and B. T. Rouse. 1993. Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J. Virol. 67:4062.
20. Henderson, R. A., M. T. Nimgaonkar, S. C. Watkins, P. D. Robbins, E. D. Ball, and O. J. Finn. 1996. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res. 56:3763.
21. Ribas, A., L. H. Butterfield, W. H. McBride, S. M. Jilani, L. A. Bui, C. M. Vollmer, R. Lau, V. B. Dissette, B. Hu, A. Y. Chenet, et al. 1997. Genetic immunization for the melanoma antigen mart-1/melan-a using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 57:2865.
22. Song, W., H. Kong, H. Carpenter, H. Torrii, R. Granstein, S. Rafii, M. A. S. Moore, and R. G. Crystal. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model tumor antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247.
23. Specht, J. M., G. Wang, M. Do, J. S. Lam, R. E. Royal, M. E. Reeves, and S. A. Rosenberg. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213.
24. Boczkowski, D., S. K. Nair, D. Snyder, and E. Gilboa. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465.
25. Brossart, P., A. W. Goldrath, E. A. Butz, S. Martin, and M. J. Bevan. 1997. Virus-mediated delivery of antigen epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158:3270.
26. Nair, S. K., D. Snyder, B. T. Rouse, and E. Gilboa. 1997. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer 70:706.
27. Porgador, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
28. Fontt, E. O., C. Heirman, K. Thielemans, and B. Vray. 1996. Granulocyte-macrophage colony-stimulating factor: involvement in control of Trypanosoma cruzi infection in mice. Infect. Immun. 64:3429.
29. Rivière, L., K. Brose, and R. C. Mulligan. 1995. Effects of retroviral design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA 92:6733.
30. Pear, W. S., M. L. Scott, and G. P. Nolan. 1997. Generation of high-titer, helper-free retroviruses by transient infection. In Methods in Molecular Medicine, Gene Therapy Protocols. J. M. Walker, ed. Humana Press, Totowa, NJ, pp. 41-57.
31. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
32. Kotani, H., P. B. I. Newton, S. Zhang, Y. L. Chiang, E. Otto, L. Weaver, R. M. Blaese, W. F. Anderson, and G. J. Mcgarrity. 1994. Improved methods of retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 5:19.
33. Reeves, M. E., R. E. Royal, J. S. Lam, S. A. Rosenberg, and P. Hwu. 1996. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 56:5672.
34. Aicher, A., J. Westermann, S. Cayeux. G. Willimsky, K. Daemen, T. Blankenstein, W. Uckert, B. Dorken, and A. Pezzutto. 1997. Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells. Exp. Hematol. 25: 39.
35. Pierre, P., S. J. Turley, E. Gatti, M. Hull, J. Meltzer, A. Mirza, K. Inaba, R. M. Steinman, and I. Mellman. 1997. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787.
36. Cella, M., A. Engering, V. Pinet, J. Pieters, and A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782.
37. Schoenberger, S. P., R. E. M. Toes, E. I. H. van der Voort, R. Offringa, and C. J. M. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
38. + T-helper and a T-killer cell. Nature 393:474.
39. Bennett, S. R. M., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. A. P. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.